Xcout Intel
Revitope Oncology, Inc.
Revitope Oncology, Inc. is a privately-held cancer immunotherapy company developing a novel platform based on redirecting viral immunity for the creation of third-generation T cell engager immunotherapies.
Subscribe to see Revitope Oncology, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Revitope Oncology, Inc. at a glance
Revitope Oncology, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $8.2M in February 2016. Xcout tracks 8 named people at Revitope Oncology, Inc., including Mark Clement (Chief Operating Officer).
Revitope Oncology, Inc. leadership
- Mark ClementChief Operating Officer
- Werner MeierChief Scientific Officer
- Andrew AllenExecutive Chairman
- Patricia GiblinSenior Vice President, Research, Ability Biologics
- Carsten ReinhardtDirector
- Louis LangeDirector
2 more named people on record for Revitope Oncology, Inc., with roles, board committees and tenure — see the full roster →
Revitope Oncology, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $8.2M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Revitope Oncology, Inc. competitors
A few of Revitope Oncology, Inc.'s closest competitors — see the full list of competitors and alternatives →
Aptevo Therapeutics Inc. is a public, clinical-stage biotechnology company headquartered in Seattle, Washington, focused on developing novel bispecific and trispecific immunotherapies for immuno-oncology.
Daylight Biotherapeutics is a biotechnology holding company operating in stealth mode in the United States. The company is developing a novel T cell engaging technology designed to decouple tumor killing from systemic immune activation.
Amphivena Therapeutics, Inc. is a clinical-stage biotechnology company located in California, United States, focused on immuno-oncology and proprietary T cell engager platforms.
Amberstone Biosciences, Inc. is an early-stage biotechnology firm that pioneers next-generation tumor-activated immunotherapeutics to discover transformative, safe, and effective treatments.
Zumutor Biologics is an immuno-oncology company incorporated in the USA, with its primary office in Cambridge, Massachusetts. The company is a leading firm in the space of targeted NK cell therapeutics and utilizes proprietary naïve human phage/yeast display technology.
Pan Cancer T develops pioneering T-cell receptor (TCR-T) cell therapies designed to empower patients' immune systems to target and overcome solid tumors. The company utilizes proprietary gene engineering to enhance T-cell fitness and persistence against unique cancer-specific intracellular targets.
Get Revitope Oncology, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Revitope Oncology, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Revitope Oncology, Inc. in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access